The experience gained with biosimilars has made it clear that copies of complex drugs are more challenging to produce and put on the market than generics. In the case of so-called nonbiological complex drugs (NBCDs), the complexity can arise either from a complex active substance or by other factors, such as formulation or route of delivery. Regulatory policies in the USA and the EU for the marketing of NBCD copies are reviewed, using glatiramer acetate copies as a case study. In the USA, they are approved and marketed as generics (although needing additional data), and so they are interchangeable with the originator. In the EU, they are managed with a hybrid application, and their interchangeability and substitution are established by individual member states.
Copies of nonbiological complex drugs: generic, hybrid or biosimilar? / P. Rocco, U.M. Musazzi, S. Franzè, P. Minghetti. - In: DRUG DISCOVERY TODAY. - ISSN 1359-6446. - 24:1(2019 Jan), pp. 250-255.
|Titolo:||Copies of nonbiological complex drugs: generic, hybrid or biosimilar?|
ROCCO, PAOLO (Primo)
MUSAZZI, UMBERTO MARIA (Secondo)
FRANZE', SILVIA (Penultimo)
MINGHETTI, PAOLA (Ultimo) (Corresponding)
|Settore Scientifico Disciplinare:||Settore CHIM/09 - Farmaceutico Tecnologico Applicativo|
|Data di pubblicazione:||gen-2019|
|Data ahead of print / Data di stampa:||4-ago-2018|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.drudis.2018.08.003|
|Appare nelle tipologie:||01 - Articolo su periodico|